Lars-Åke Levin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lars-Åke Levin has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Giuseppe Boriani
Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, 41124 Modena, Italy
3 shared publications - Johan Lyth
Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden
3 shared publications - Lars Bernfort
Linköpings universitet, Avdelningen för samhälle och hälsa
3 shared publications - Renate B. Schnabel
Department of Cardiology, University Heart & Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf , Hamburg
3 shared publications - Ben Freedman
Heart Research Institute, Sydney Medical School, Charles Perkins Center, and Cardiology Department, The University of Sydney, Sydney, NSW, Australia (B.F.).
2 shared publications - Claire M. Buckley
School of Public Health Cork County Cork University College Cork
2 shared publications
Latest Publications
- Open Access
- 18 November 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 894-902
Economic burden of hospital-requiring infections and venous thromboembolism in the last year of life in advanced breast cancer: a complication-specific cost analysis
Background and purpose: End-of-life healthcare costs in advanced breast cancer (ABC) are substantial, yet the contribution of acute, life-threatening complications, hospital-requiring infections and venous thromboembolism (VTE), remains uncharacterised. We quantified adjusted complication-specific costs. Patient/material and methods: Population-based cohort study of 1,363 women who died with ABC in the Stockholm Region (2015–2023). Healthcare costs during the last 12 months of life were estimated using the Region Stockholm simulated cost (SIM) model and stratified by complication status, age group, and Hospital Frailty Risk Score (HFRS). Generalised linear models estimated the independent associations between hospital-requiring infections, VTE and total costs, adjusting sequentially for age, frailty risk, and systemic therapy. Results: Overall mean costs were 597 thousand SEK (tSEK; 95% CI: 578–616). Hospital-requiring infections occurred in 18% of patients and were independently associated with 29% higher costs after full adjustment (cost ratio 1.29, 95% confidence interval [CI]: 1.20–1.39). VTE occurred in 8% of patients, of whom 80% had pulmonary embolism; it was associated with higher costs unadjusted (1.16, p = 0.010) but not after adjustment for frailty risk (1.08, 95% CI: 0.97–1.21). Concomitant VTE (27 patients, 11% of those infected) gave costs similar to infection alone. High frailty risk showed the strongest independent association with cost in the infection model (cost ratio 1.54, 95% CI: 1.34–1.78). Interpretation: Hospital-requiring infections were independently associated with higher end-of-life costs in ABC; VTE was not, once frailty risk was adjusted for. These findings add a complication-specific dimension to frailty-based risk stratification and support targeted prevention in end-of-life care.
- 18 November 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 894-902
Open AccessEconomic burden of hospital-requiring infections and venous thromboembolism in the last year of life in advanced breast cancer: a complication-specific cost analysis
Background and purpose: End-of-life healthcare costs in advanced breast cancer (ABC) are substantial, yet the contribution of acute, life-threatening complications, hospital-requiring infections and venous thromboembolism (VTE), remains uncharacterised. We quantified adjusted complication-specific costs. Patient/material and methods: Population-based cohort study of 1,363 women who died with ABC in the Stockholm Region (2015–2023). Healthcare costs during the last 12 months of life were estimated using the Region Stockholm simulated cost (SIM) model and stratified by complication status, age group, and Hospital Frailty Risk Score (HFRS). Generalised linear models estimated the independent associations between hospital-requiring infections, VTE and total costs, adjusting sequentially for age, frailty risk, and systemic therapy. Results: Overall mean costs were 597 thousand SEK (tSEK; 95% CI: 578–616). Hospital-requiring infections occurred in 18% of patients and were independently associated with 29% higher costs after full adjustment (cost ratio 1.29, 95% confidence interval [CI]: 1.20–1.39). VTE occurred in 8% of patients, of whom 80% had pulmonary embolism; it was associated with higher costs unadjusted (1.16, p = 0.010) but not after adjustment for frailty risk (1.08, 95% CI: 0.97–1.21). Concomitant VTE (27 patients, 11% of those infected) gave costs similar to infection alone. High frailty risk showed the strongest independent association with cost in the infection model (cost ratio 1.54, 95% CI: 1.34–1.78). Interpretation: Hospital-requiring infections were independently associated with higher end-of-life costs in ABC; VTE was not, once frailty risk was adjusted for. These findings add a complication-specific dimension to frailty-based risk stratification and support targeted prevention in end-of-life care.
- Open Access
- 6 February 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 75-82
Healthcare costs and resource use in advanced breast cancer at the end of life: a register study
Background and purpose: Advanced breast cancer (ABC) involves substantial end-of-life (EOL) healthcare use and costs. Understanding cost drivers can inform care delivery and resource allocation.Patient/material and methods: We conducted a retrospective, population-based study of individuals (n = 1,437) who died with breast cancer in the Stockholm Region (2015–2023). Healthcare utilization and costs during the last 12 months of life were obtained from the Stockholm Regional Healthcare Data Repository (VAL) and estimated using the Region Stockholm cost model. Variables included age, sex, socioeconomic status (Mosaic), Charlson Comorbidity Index, Hospital Frailty Risk Score (HFRS), systemic therapy, and place of death. Descriptive statistics and generalized linear models assessed cost associations.Results: Total costs rose toward EOL, increasing 140% in the final 3 months versus the prior quarter. Hospitalizations and specialized palliative care drove costs, while outpatient visits declined. Younger age (18–69 years), high frailty (HFRS > 15), and systemic therapy were independently associated with higher costs. Hospital death was associated with lower expenditures than dying elsewhere (rate ratio [RR]: 0.84, 95% confidence interval [CI]: 0.78–0.91). The top 5% of cost users were mainly younger, frail patients receiving systemic therapy.Interpretation: ABC-related costs escalate in the final year of life, driven by hospitalizations, palliative care, and systemic therapies. Younger, frailer patients incur higher costs, while those dying in hospital settings are associated with lower costs. Early palliative integration and frailty-based risk stratification were associated with distinct patterns of healthcare utilization and costs toward the EOL.
- 6 February 2026
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 65, 75-82
Open AccessHealthcare costs and resource use in advanced breast cancer at the end of life: a register study
Background and purpose: Advanced breast cancer (ABC) involves substantial end-of-life (EOL) healthcare use and costs. Understanding cost drivers can inform care delivery and resource allocation.Patient/material and methods: We conducted a retrospective, population-based study of individuals (n = 1,437) who died with breast cancer in the Stockholm Region (2015–2023). Healthcare utilization and costs during the last 12 months of life were obtained from the Stockholm Regional Healthcare Data Repository (VAL) and estimated using the Region Stockholm cost model. Variables included age, sex, socioeconomic status (Mosaic), Charlson Comorbidity Index, Hospital Frailty Risk Score (HFRS), systemic therapy, and place of death. Descriptive statistics and generalized linear models assessed cost associations.Results: Total costs rose toward EOL, increasing 140% in the final 3 months versus the prior quarter. Hospitalizations and specialized palliative care drove costs, while outpatient visits declined. Younger age (18–69 years), high frailty (HFRS > 15), and systemic therapy were independently associated with higher costs. Hospital death was associated with lower expenditures than dying elsewhere (rate ratio [RR]: 0.84, 95% confidence interval [CI]: 0.78–0.91). The top 5% of cost users were mainly younger, frail patients receiving systemic therapy.Interpretation: ABC-related costs escalate in the final year of life, driven by hospitalizations, palliative care, and systemic therapies. Younger, frailer patients incur higher costs, while those dying in hospital settings are associated with lower costs. Early palliative integration and frailty-based risk stratification were associated with distinct patterns of healthcare utilization and costs toward the EOL.
- Open Access
- 28 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (2) , 170-187
Recent-onset atrial fibrillation: challenges and opportunities
Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
- 28 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (2) , 170-187
Open AccessRecent-onset atrial fibrillation: challenges and opportunities
Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
- Open Access
- 25 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (1) , 83-92
Cost-effectiveness of atrial fibrillation screening programmes across European nations
Aims: Due to the ageing population in Europe, a significant increase in the incidence of atrial fibrillation (AF) is anticipated. This is predicted to have a detrimental impact on public health costs, particularly among the elderly, because of an increased number of stroke cases. Early detection of AF is crucial for initiating treatment with oral anticoagulants (OACs) to reduce the risk of stroke. This study aims to assess the cost-effectiveness of implementing AF screening programmes in eight European countries: Denmark, Germany, Ireland, Italy, the Netherlands, Serbia, Spain, and Sweden. Methods and results: The analysis concerned invitation to AF population screening for 75-year-olds. A Markov cohort model was used, considering the prevalence of AF, screening yield, the use of different OACs, estimated clinical events, mortality, quality of life and costs. The model used country-specific parameters to produce specific cost-effectiveness estimates. Probabilistic sensitivity analyses were conducted to assess the impact of parametric uncertainties on the results. Inviting 75-year-olds to AF screening proved to be cost-effective across all eight countries analysed. In all countries, the strategy was dominant, meaning that quality-adjusted life-years were gained at lower costs. The time to financial break-even ranged from 6 to 14 years. Conclusion: This study indicates that population-based AF screening of 75-year-olds is a cost-effective strategy across eight European countries, meaning that adoption of such a strategy has the potential to make healthcare systems in these countries more efficient. The heterogeneity among European countries suggests that AF screening programmes may need to be tailored to the specific healthcare systems and conditions of each nation.
- 25 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 12 (1) , 83-92
Open AccessCost-effectiveness of atrial fibrillation screening programmes across European nations
Aims: Due to the ageing population in Europe, a significant increase in the incidence of atrial fibrillation (AF) is anticipated. This is predicted to have a detrimental impact on public health costs, particularly among the elderly, because of an increased number of stroke cases. Early detection of AF is crucial for initiating treatment with oral anticoagulants (OACs) to reduce the risk of stroke. This study aims to assess the cost-effectiveness of implementing AF screening programmes in eight European countries: Denmark, Germany, Ireland, Italy, the Netherlands, Serbia, Spain, and Sweden. Methods and results: The analysis concerned invitation to AF population screening for 75-year-olds. A Markov cohort model was used, considering the prevalence of AF, screening yield, the use of different OACs, estimated clinical events, mortality, quality of life and costs. The model used country-specific parameters to produce specific cost-effectiveness estimates. Probabilistic sensitivity analyses were conducted to assess the impact of parametric uncertainties on the results. Inviting 75-year-olds to AF screening proved to be cost-effective across all eight countries analysed. In all countries, the strategy was dominant, meaning that quality-adjusted life-years were gained at lower costs. The time to financial break-even ranged from 6 to 14 years. Conclusion: This study indicates that population-based AF screening of 75-year-olds is a cost-effective strategy across eight European countries, meaning that adoption of such a strategy has the potential to make healthcare systems in these countries more efficient. The heterogeneity among European countries suggests that AF screening programmes may need to be tailored to the specific healthcare systems and conditions of each nation.
- Open Access
- 31 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 26 (Supplement) , iv19-iv32
The budget impact of implementing atrial fibrillation-screening in European countries
A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from €10 in Ireland to €122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers’ costs, introducing population screening for AF will result in savings of stroke-related costs.
- 31 July 2024
- Published by Oxford University Press (OUP) in European Heart Journal Supplements
- Vol. 26 (Supplement) , iv19-iv32
Open AccessThe budget impact of implementing atrial fibrillation-screening in European countries
A budget impact analysis estimates the short-term difference between the cost of the current treatment strategy and a new treatment strategy, in this case to implement population screening for atrial fibrillation (AF). The aim of this study is to estimate the financial impact of implementing population-based AF-screening of 75-year-olds compared with the current setting of no screening from a healthcare payer perspective in eight European countries. The net budget impact of AF-screening was estimated in country-specific settings for Denmark, Germany, Ireland, Italy, Netherlands, Serbia, Spain, and Sweden. Country-specific parameters were used to allow for variations in healthcare systems and to reflect the healthcare sector in the country of interest. Similar results can be seen in all countries AF-screening incurs savings of stroke-related costs since AF treatment reduces the number of strokes. However, the increased number of detected AF and higher drug acquisition will increase the drug costs as well as the costs of physician- and control visits. The net budget impact per invited varied from €10 in Ireland to €122 in the Netherlands. The results showed the increased costs of implementing AF-screening were mainly driven by increased drug costs and screening costs. In conclusion, across Europe, though the initial cost of screening and more frequent use of oral anti-coagulants will increase the healthcare payers’ costs, introducing population screening for AF will result in savings of stroke-related costs.
- Open Access
- 1 December 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2200245
Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care
PURPOSE: The combination of whole-genome and transcriptome sequencing (WGTS) is expected to transform diagnosis and treatment for patients with cancer. WGTS is a comprehensive precision diagnostic test that is starting to replace the standard of care for oncology molecular testing in health care systems around the world; however, the implementation and widescale adoption of this best-in-class testing is lacking. METHODS: Here, we address the barriers in integrating WGTS for cancer diagnostics and treatment selection and answer questions regarding utility in different cancer types, cost-effectiveness and affordability, and other practical considerations for WGTS implementation. RESULTS: We review the current studies implementing WGTS in health care systems and provide a synopsis of the clinical evidence and insights into practical considerations for WGTS implementation. We reflect on regulatory, costs, reimbursement, and incidental findings aspects of this test. CONCLUSION: WGTS is an appropriate comprehensive clinical test for many tumor types and can replace multiple, cascade testing approaches currently performed. Decreasing sequencing cost, increasing number of clinically relevant aberrations and discovery of more complex biomarkers of treatment response, should pave the way for health care systems and laboratories in implementing WGTS into clinical practice, to transform diagnosis and treatment for patients with cancer.
- 1 December 2022
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 6 (6) , e2200245
Open AccessImplementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care
PURPOSE: The combination of whole-genome and transcriptome sequencing (WGTS) is expected to transform diagnosis and treatment for patients with cancer. WGTS is a comprehensive precision diagnostic test that is starting to replace the standard of care for oncology molecular testing in health care systems around the world; however, the implementation and widescale adoption of this best-in-class testing is lacking. METHODS: Here, we address the barriers in integrating WGTS for cancer diagnostics and treatment selection and answer questions regarding utility in different cancer types, cost-effectiveness and affordability, and other practical considerations for WGTS implementation. RESULTS: We review the current studies implementing WGTS in health care systems and provide a synopsis of the clinical evidence and insights into practical considerations for WGTS implementation. We reflect on regulatory, costs, reimbursement, and incidental findings aspects of this test. CONCLUSION: WGTS is an appropriate comprehensive clinical test for many tumor types and can replace multiple, cascade testing approaches currently performed. Decreasing sequencing cost, increasing number of clinically relevant aberrations and discovery of more complex biomarkers of treatment response, should pave the way for health care systems and laboratories in implementing WGTS into clinical practice, to transform diagnosis and treatment for patients with cancer.
- Open Access
- 9 November 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (3) , 196-204
Cost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study
Aims: Previous studies on the cost-effectiveness of screening for atrial fibrillation (AF) are based on assumptions of long-term clinical effects. The STROKESTOP study, which randomised 27 975 persons aged 75/76 years into a screening invitation group and a control group, has a median follow-up time of 6.9 years. The aim of this study was to estimate the cost-effectiveness of population-based screening for AF using clinical outcomes. Methods and results: The analysis is based on a Markov cohort model. The prevalence of AF, the use of oral anticoagulation, clinical event data, and all-cause mortality were taken from the STROKESTOP study. The cost for clinical events, age-specific utilities, utility decrement due to stroke, and stroke death was taken from the literature. Uncertainty in the model was considered in a probabilistic sensitivity analysis. Per 1000 individuals invited to the screening, there were 77 gained life years and 65 gained quality-adjusted life years. The incremental cost was €1.77 million lower in the screening invitation group. Gained quality-adjusted life years to a lower cost means that the screening strategy was dominant. The result from 10 000 Monte Carlo simulations showed that the AF screening strategy was cost-effective in 99.2% and cost-saving in 92.7% of the simulations. In the base-case scenario, screening of 1000 individuals resulted in 10.6 [95% confidence interval (CI): −22.5 to 1.4] fewer strokes (8.4 ischaemic and 2.2 haemorrhagic strokes), 1.0 (95% CI: −1.9 to 4.1) more cases of systemic embolism, and 2.9 (95% CI: −18.2 to 13.1) fewer bleedings associated with hospitalization. Conclusion: Based on the STROKESTOP study, this analysis shows that a broad AF screening strategy in an elderly population is cost-effective. Efforts should be made to increase screening participation.
- 9 November 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (3) , 196-204
Open AccessCost-effectiveness of population screening for atrial fibrillation: the STROKESTOP study
Aims: Previous studies on the cost-effectiveness of screening for atrial fibrillation (AF) are based on assumptions of long-term clinical effects. The STROKESTOP study, which randomised 27 975 persons aged 75/76 years into a screening invitation group and a control group, has a median follow-up time of 6.9 years. The aim of this study was to estimate the cost-effectiveness of population-based screening for AF using clinical outcomes. Methods and results: The analysis is based on a Markov cohort model. The prevalence of AF, the use of oral anticoagulation, clinical event data, and all-cause mortality were taken from the STROKESTOP study. The cost for clinical events, age-specific utilities, utility decrement due to stroke, and stroke death was taken from the literature. Uncertainty in the model was considered in a probabilistic sensitivity analysis. Per 1000 individuals invited to the screening, there were 77 gained life years and 65 gained quality-adjusted life years. The incremental cost was €1.77 million lower in the screening invitation group. Gained quality-adjusted life years to a lower cost means that the screening strategy was dominant. The result from 10 000 Monte Carlo simulations showed that the AF screening strategy was cost-effective in 99.2% and cost-saving in 92.7% of the simulations. In the base-case scenario, screening of 1000 individuals resulted in 10.6 [95% confidence interval (CI): −22.5 to 1.4] fewer strokes (8.4 ischaemic and 2.2 haemorrhagic strokes), 1.0 (95% CI: −1.9 to 4.1) more cases of systemic embolism, and 2.9 (95% CI: −18.2 to 13.1) fewer bleedings associated with hospitalization. Conclusion: Based on the STROKESTOP study, this analysis shows that a broad AF screening strategy in an elderly population is cost-effective. Efforts should be made to increase screening participation.
- Open Access
- 27 August 2020
- Published by Springer Nature in BMC Health Services Research
- Vol. 20 (1) , 1-11
A pain relieving reimbursement program? Effects of a value-based reimbursement program on patient reported outcome measures
Background: Value-based reimbursement programs have become increasingly common. However, little is known about the effect of such programs on patient reported outcomes. Thus, the aim of this study was to analyze the effect of introducing a value-based reimbursement program on patient reported outcome measures and to explore whether a selection bias towards less complicated patients occurred. Methods: This is a retrospective observational study with a before and after design based on the introduction of a value-based reimbursement program in Region Stockholm, Sweden. We analyzed patient level data from inpatient and outpatient care of patients undergoing lumbar spine surgery during 2006–2015. Patient reported outcome measures used was Global Assessment, EQ-5D-3L and Oswestry Disability Index. The case-mix of surgically treated patients was analyzed using medical and socioeconomic factors. Results: The value-based reimbursement program did not have any effect on targeted or non-targeted patient reported outcome measures. Moreover, the share of surgically treated patients with risk factors such as having comorbidities and being born outside of Europe increased after the introduction. Hence, the value-based reimbursement program did not encourage discrimination against sicker patients. However, the income was higher among patients surgically treated after the introduction of the value-based reimbursement. This indicates that a value-based reimbursement program may contribute to increased inequalities in access to healthcare. Conclusions: The value-based reimbursement program did not have any effect on patient reported outcome measures. Our study contributes to the understanding of the effects of a value-based reimbursement program on patient reported outcome measures and to what extent cherry-picking arises.
- 27 August 2020
- Published by Springer Nature in BMC Health Services Research
- Vol. 20 (1) , 1-11
Open AccessA pain relieving reimbursement program? Effects of a value-based reimbursement program on patient reported outcome measures
Background: Value-based reimbursement programs have become increasingly common. However, little is known about the effect of such programs on patient reported outcomes. Thus, the aim of this study was to analyze the effect of introducing a value-based reimbursement program on patient reported outcome measures and to explore whether a selection bias towards less complicated patients occurred. Methods: This is a retrospective observational study with a before and after design based on the introduction of a value-based reimbursement program in Region Stockholm, Sweden. We analyzed patient level data from inpatient and outpatient care of patients undergoing lumbar spine surgery during 2006–2015. Patient reported outcome measures used was Global Assessment, EQ-5D-3L and Oswestry Disability Index. The case-mix of surgically treated patients was analyzed using medical and socioeconomic factors. Results: The value-based reimbursement program did not have any effect on targeted or non-targeted patient reported outcome measures. Moreover, the share of surgically treated patients with risk factors such as having comorbidities and being born outside of Europe increased after the introduction. Hence, the value-based reimbursement program did not encourage discrimination against sicker patients. However, the income was higher among patients surgically treated after the introduction of the value-based reimbursement. This indicates that a value-based reimbursement program may contribute to increased inequalities in access to healthcare. Conclusions: The value-based reimbursement program did not have any effect on patient reported outcome measures. Our study contributes to the understanding of the effects of a value-based reimbursement program on patient reported outcome measures and to what extent cherry-picking arises.
- Open Access
- 1 March 2020
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 13, 475-489
Factors Associated with Life Satisfaction in Older Adults with Chronic Pain (PainS65+)
Background: Chronic pain in later life is a worldwide problem. In younger patients, chronic pain affects life satisfaction negatively; however, it is unknown whether this outcome will extend into old age. Objective: This study examines which factors determine life satisfaction in older adults who suffer from chronic pain with respect to socio-demographics, lifestyle behaviors, pain, and comorbidities. Methods: This cross-sectional study recruited a random sample of people ≥ 65 years old living in south-eastern Sweden (N= 6611). A postal survey addressed pain aspects and health experiences. Three domains from the Life Satisfaction Questionnaire (LiSat-11) were used to capture the individual’s estimations of overall satisfaction (LiSat-life), somatic health (LiSat-somhealth), and psychological health (LiSat-psychhealth). Results: Respondents with chronic pain (2790, 76.2± 7.4 years old) rated lower on life satisfaction than those without chronic pain, with medium effect size (ES) on LiSat-somhealth (r = 0.38, P < 0.001) and small ES on the other two domains (r < 0.3). Among the respondents with chronic pain, severe pain (OR 0.29– 0.59) and pain spreading (OR 0.87– 0.95) were inversely associated with all three domains of the LiSat-11. Current smoking, alcohol overconsumption, and obesity negatively affected one or more domains of the LiSat-11. Most comorbidities were negatively related to LiSat-somhealth, and some comorbidities affected the other two domains. For example, having tumour or cancer negatively affected both LiSat-life (OR 0.62, 95% CI 0.44– 0.88) and LiSat-somhealth (OR 0.42, 95% CI 0.24– 0.74). Anxiety or depression disorders had a negative relationship both for LiSat-life (OR 0.54, 95% CI 0.38– 0.78) and LiSat-psychhealth (OR 0.10, 95% CI 0.06– 0.14). Conclusion: Older adults with chronic pain reported lower life satisfaction but the difference from their peers without chronic pain was trivial, except for satisfaction with somatic health. Pain management in old age needs to consider comorbidities and severe pain to improve patients’ life satisfaction.
- 1 March 2020
- Published by Taylor & Francis in Journal of Pain Research
- Vol. ume 13, 475-489
Open AccessFactors Associated with Life Satisfaction in Older Adults with Chronic Pain (PainS65+)
Background: Chronic pain in later life is a worldwide problem. In younger patients, chronic pain affects life satisfaction negatively; however, it is unknown whether this outcome will extend into old age. Objective: This study examines which factors determine life satisfaction in older adults who suffer from chronic pain with respect to socio-demographics, lifestyle behaviors, pain, and comorbidities. Methods: This cross-sectional study recruited a random sample of people ≥ 65 years old living in south-eastern Sweden (N= 6611). A postal survey addressed pain aspects and health experiences. Three domains from the Life Satisfaction Questionnaire (LiSat-11) were used to capture the individual’s estimations of overall satisfaction (LiSat-life), somatic health (LiSat-somhealth), and psychological health (LiSat-psychhealth). Results: Respondents with chronic pain (2790, 76.2± 7.4 years old) rated lower on life satisfaction than those without chronic pain, with medium effect size (ES) on LiSat-somhealth (r = 0.38, P < 0.001) and small ES on the other two domains (r < 0.3). Among the respondents with chronic pain, severe pain (OR 0.29– 0.59) and pain spreading (OR 0.87– 0.95) were inversely associated with all three domains of the LiSat-11. Current smoking, alcohol overconsumption, and obesity negatively affected one or more domains of the LiSat-11. Most comorbidities were negatively related to LiSat-somhealth, and some comorbidities affected the other two domains. For example, having tumour or cancer negatively affected both LiSat-life (OR 0.62, 95% CI 0.44– 0.88) and LiSat-somhealth (OR 0.42, 95% CI 0.24– 0.74). Anxiety or depression disorders had a negative relationship both for LiSat-life (OR 0.54, 95% CI 0.38– 0.78) and LiSat-psychhealth (OR 0.10, 95% CI 0.06– 0.14). Conclusion: Older adults with chronic pain reported lower life satisfaction but the difference from their peers without chronic pain was trivial, except for satisfaction with somatic health. Pain management in old age needs to consider comorbidities and severe pain to improve patients’ life satisfaction.
- 1 October 2008
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 24 (4) , 488-494
Do individuals consider expected income when valuing health states?
Objectives: The purpose of this study was to empirically explore whether individuals take their expected income into consideration when directly valuing predefined health states. This was intended to help determine how to handle productivity costs due to morbidity in a cost-effectiveness analysis. Methods: Two hundred students each valued four hypothetical health states by using time trade-off (TTO) and a visual analogue scale (VAS). The students were randomly assigned to two groups. One group was simply asked, without mentioning income, to value the different health states (the non-income group). The other group was explicitly asked to consider their expected income in relation to the health states in their valuations (the income group). Results: For health states that are usually assumed to have a large effect on income, the valuations made by the income group seemed to be lower than the valuations made by the non-income group. Among the students in the non-income group, 96 percent stated that they had not thought about their expected income when they valued the health states. In the income group, 40 percent believed that their expected income had affected their valuations of the health states. Conclusion: The results show that, as long as income is not mentioned, most individuals do not seem to consider their expected income when they value health states. This indicates that productivity costs due to morbidity are not captured within individuals' health state valuations. These findings, therefore, suggest that productivity costs due to morbidity should be included as a cost in cost-effectiveness analyses.
- 1 October 2008
- Published by Cambridge University Press (CUP) in International Journal of Technology Assessment in Health Care
- Vol. 24 (4) , 488-494
Do individuals consider expected income when valuing health states?
Objectives: The purpose of this study was to empirically explore whether individuals take their expected income into consideration when directly valuing predefined health states. This was intended to help determine how to handle productivity costs due to morbidity in a cost-effectiveness analysis. Methods: Two hundred students each valued four hypothetical health states by using time trade-off (TTO) and a visual analogue scale (VAS). The students were randomly assigned to two groups. One group was simply asked, without mentioning income, to value the different health states (the non-income group). The other group was explicitly asked to consider their expected income in relation to the health states in their valuations (the income group). Results: For health states that are usually assumed to have a large effect on income, the valuations made by the income group seemed to be lower than the valuations made by the non-income group. Among the students in the non-income group, 96 percent stated that they had not thought about their expected income when they valued the health states. In the income group, 40 percent believed that their expected income had affected their valuations of the health states. Conclusion: The results show that, as long as income is not mentioned, most individuals do not seem to consider their expected income when they value health states. This indicates that productivity costs due to morbidity are not captured within individuals' health state valuations. These findings, therefore, suggest that productivity costs due to morbidity should be included as a cost in cost-effectiveness analyses.